Clinical Management of Embryonal Tumor with Multilayered Rosettes: The CCMC Experience
Open Access
Abstract
Objective: Embryonal tumors with multilayered rosettes (ETMRs) are highly aggressive pediatric brain tumors with poor prognosis. No standard treatment strategy for them exists because of their rarity. This study aimed to share experiences on the clinical diagnosis and treatment of ETMRs at China Children’s Medical Center (CCMC). Methods: Patients who received a diagnosis of an ETMR between January 2017 and June 2020 were included. Clinical characteristics, such as age of onset, tumor size, stage, tumor site, treatment strategy, and clinical outcome, were retrospectively analyzed. Results: There were four boys and one girl within 4 years who received a diagnosis during this 4-year timeframe, and were thus included. The average age of morbidity was 29 months (range 16–66 months). The common clinical presentation was headaches and nausea caused by intracranial hypertension. All four patients were chromosome 19 microRNA cluster (C19MC) amplification positive. Two patients achieved complete remission, and one patient attained partial remission after multimodal treatment. Of the two deaths, one died from the rapid progression of the disease and another from tumor-related complications. Conclusion: ETMRs are extremely rare brain tumors with a high, early mortality in children. Surgery is the mainstream treatment for ETMRs. Some patients may also benefit from postoperative adjuvant chemotherapy and radiotherapy.Keywords
Funding Information
- Innovative Research Program of Xiangyang No.1 People’s Hospital (XYY2021Q02)
- Platform Special Fund for Scientific Research of Xiangyang No.1 People’s Hospital (XYY2022P05)
- Key projects of Xiangyang Science and Technology Bureau (2021YL26)
This publication has 22 references indexed in Scilit:
- Validity and Reliability of the US National Cancer Institute’s Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)JAMA Oncology, 2015
- Embryonal tumors with multilayered rosettes in children: the SFCE experienceChild's Nervous System, 2015
- Treatment outcomes and late toxicities in patients with embryonal central nervous system tumorsRadiation Oncology, 2014
- CNS-PNETs with C19MC amplification and/or LIN28 expression comprise a distinct histogenetic diagnostic and therapeutic entityActa Neuropathologica, 2014
- Embryonal tumor with abundant neuropil and true rosettes (ETANTR), ependymoblastoma, and medulloepithelioma share molecular similarity and comprise a single clinicopathological entityActa Neuropathologica, 2013
- Fusion of TTYH1 with the C19MC microRNA cluster drives expression of a brain-specific DNMT3B isoform in the embryonal brain tumor ETMRNature Genetics, 2013
- LIN28A immunoreactivity is a potent diagnostic marker of embryonal tumor with multilayered rosettes (ETMR)Acta Neuropathologica, 2012
- Response assessment in recurrent glioblastoma treated with irinotecan-bevacizumab: comparative analysis of the Macdonald, RECIST, RANO, and RECIST + F criteriaNeuro-Oncology, 2012
- Focal genomic amplification at 19q13.42 comprises a powerful diagnostic marker for embryonal tumors with ependymoblastic rosettesActa Neuropathologica, 2010
- Outcome of children less than three years old at diagnosis with non‐metastatic medulloblastoma treated with chemotherapy on the “Head Start” I and II protocolsPediatric Blood & Cancer, 2008